ENZC
Enzolytics Inc.

Enzolytics, Inc. (OTC PINK: ENZC) ("enzolytics.com”) (the “Company” or “Enzolytics”) announced today the beginning steps of a capital restructuring plan meant to facilitate its current and future acquisition and financing strategy. Currently the Company is in negotiations with several acquisitions opportunities that will necessitate a more reasonable capital structure for the implementation of its plan and completion of the planned transactions.

The initial step, in this innovative tactic, will be the execution, upon approval, of a 1:1,000 reverse of the Enzolytics common shares, as well as the common shares imbedded in the convertible Preferred Series B, C and F. The directors, majority shareholders and executive management believe this restructuring will provide the Company with the ability as well as the flexibility to negotiate better terms and protect the shareholder value of our existing base, while cleaning up issues from the prior management and board. 

Additionally, Sagaliam Acquisition Corp. (“SAGA”) has informed the Company that Dr. Keith Tong has agreed to join the SAGA board. Enzolytics believes that this development, as well as the planned equity restructuring, will hasten the progress of not only the cutting-edge technology acquisition of a non-dilutable thirty percent (30%) ownership in the Room Temperature Single Photon Avalanche Diode (SPAD) Project (the "SPAD Project") headed by Dr. Tong announced in June of 2024, but also the audit and approval of the application for inclusion on the OTC X exchange. 

The following is an excerpt from the bio provided to SAGA:
“Dr. Keith Tong
Dr. Keith Tong holds a Ph.D. in Electrical, Electronics, and Computing Engineering with a focus on Physics from the University of Edinburgh, as well as an MBA from the University of Hong Kong. His career began in aviation engineering, where he served as a Design Staff Engineer for over five years at Hawker Siddeley Aviation in London, focusing on Rolls-Royce flight engines. He later expanded his technical expertise through key roles at the Civil Aviation Administration of China and various other industry positions.
As the Founder and CEO of HF Group, Dr. Tong leads a multifaceted organization that includes HFS Flight Services, HF Consultants (Xinhua Net U.S. channel agent), HF Consultants (China), HF Aeronautical Corp., HF Food Management, and Deppon® Logistic Group. HF Group is a distinguished member of the China General Chamber of Commerce (USA) in Los Angeles, emphasizing Dr. Tong's commitment to fostering international business relations.
In addition to his corporate leadership, Dr. Tong is an active member of The Pacific Club in Newport Beach, California, a prestigious social club. With over 15 years of experience as a Technical Administrator in semiconductor design and manufacturing, he specializes in CMOS, SiGe, and silicon photonics technologies, making significant contributions to advancements in these fields.
Dr. Tong also serves as the President of the International Cultural and Educational Exchange Foundation, a nonprofit organization based in Irvine, California. In this role, he leads initiatives promoting cross-cultural education and collaboration, reflecting his dedication to technological innovation and community development.

With decades of experience in management and consulting within the clinical research and aviation industries across Bolivia, Hong Kong, and the United States, Dr. Keith Tong exemplifies a unique blend of engineering expertise, business acumen, and nonprofit leadership.”
Steve Sharabura, the CEO of Enzolytics commented, “ The Company is fortunate to have the current opportunities that have been in development since the change in the Board and management in March of this year. The restructuring of its capital structure will facilitate our efforts to bring these to a close. We expect to announce a major new opportunity in the coming weeks as a result of the planned new equity structure. ”

About Enzolytics, Inc.

Enzolytics, Inc. is transitioning from solely a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to include the additional contracted service areas of sales, marketing and distribution focusing on medical devices, medical testing and nutraceutical products.

Forward Looking Statements
 
The disclosure herein includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Company’s ability to enter into a definitive business combination agreement and Company’s ability to obtain the financing necessary to consummate the potential business combination transaction. These statements are based on various assumptions and on the current expectations of Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Company. These forward-looking statements are subject to a number of risks and uncertainties, including: Company’s ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction; the risk that the approval of the stockholders of Company for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Company; the amount of redemption requests made by Company’s stockholders and the amount of funds remaining in Company’s trust account after satisfaction of such requests; those factors discussed in Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under the heading “Risk Factors,” and other documents of Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Company presently does not know or that Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Company’s expectations, plans or forecasts of future events and views as of the date hereof. Company anticipates that subsequent events and developments will cause Company’s assessments to change. However, while Company may elect to update these forward-looking statements at some point in the future, Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Company’s assessments as of any date subsequent to the date of this disclosure statement. Accordingly, undue reliance should not be placed upon the forward-looking statements.
 
CONTACT INFORMATION
Enzolytics, Inc.
Steve Sharabura, Chief Executive Officer
1101 Raintree Circle, Suite 130
Allen, Texas 75013
Tel: (845) 925-4597
 X/Twitter: @EnzolyticsInc